Thu, March 17, 2011
Wed, March 16, 2011
Tue, March 15, 2011
Mon, March 14, 2011
[ Mon, Mar 14th 2011 ] - Market Wire
30 AM E.T.
Sun, March 13, 2011
Sat, March 12, 2011
Fri, March 11, 2011
[ Fri, Mar 11th 2011 ] - Market Wire
Covidien????????????????FDA??
Thu, March 10, 2011
Wed, March 9, 2011
Tue, March 8, 2011
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011

DUSA Pharmaceuticals to Present at Roth Capital Partners 23rd Annual OC Growth Stock Conference


//health-fitness.news-articles.net/content/2011/ .. ners-23rd-annual-oc-growth-stock-conference.html
Published in Health and Fitness on Wednesday, March 9th 2011 at 4:25 GMT by Market Wire   Print publication without navigation


WILMINGTON, Mass.--([ BUSINESS WIRE ])--DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a specialty pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform for the prevention and treatment of dermatological skin conditions, announced that Bob Doman, President and Chief Executive Officer, will present a corporate overview at the Roth 23rd Annual OC Growth Stock Conference. The conference is being held at the Ritz-Carlton Laguna Niguel, Dana Point, California on March 13-16, 2011. Mr. Doman is scheduled to present at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 15, 2011. Interested parties can access the live webcast of the presentation at [ www.dusapharma.com ]. An archived version of the presentation will be available on the DUSA website approximately three hours following the presentation.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® PDT technology platform, and other dermatology products. Levulan® Kerastick® for topical solution plus DUSAa™s BLU-U® blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp. DUSA also markets other dermatology products, including ClindaReach®. DUSA is based in Wilmington, Mass. Please visit our website at [ www.dusapharma.com ].


Publication Contributing Sources